about
Options for empagliflozin in combination therapy in type 2 diabetes mellitusDifferential pharmacology and clinical utility of empagliflozin in type 2 diabetesSodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectivesManagement of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistanceEfficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitusComparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysisSGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysisMedical Management of Diabesity: Do We Have Realistic Targets?Diabetic ketoacidosis: a challenging diabetes phenotypeImpact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Sodium-glucose co-transporter-2 inhibitor use and dietary carbohydrate intake in Japanese individuals with type 2 diabetes: A randomized, open-label, 3-arm parallel comparative, exploratory study.Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsNovel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusComparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis.Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysisRenal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitusSodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight.Incidence and outcome of adults with diabetic ketoacidosis admitted to ICUs in Australia and New ZealandSodium glucose cotransporter 2 inhibition in the diabetic kidney: an updatePost-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on OutcomesA Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes.Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitusEuglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin.An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patientsThe renal effects of SGLT2 inhibitors and a mini-review of the literature.Use of oral combination therapy for type 2 diabetes in primary care: Meeting individualized patient goals.Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Role of incretin-based therapies and sodium-glucose co-transporter-2 inhibitors as adjuncts to insulin therapy in Type 2 diabetes, with special reference to IDegLira.Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.Implications of the EMPA-REG Trial for Clinical Care and Research.The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on mineral metabolism and bone in patients with type 2 diabetes mellitus.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.Impact of empagliflozin in patients with diabetes and heart failure.
P2860
Q26745771-FA9BF5C4-25CB-451C-8797-F841CB4DC9F3Q26749281-0A3E760D-1885-40FB-85BC-736AF53C1A70Q26767263-247E9093-E1D5-43B7-B3CF-59FE018C13BDQ26775379-4031663D-38D8-47BC-BBC5-16B8E279735BQ26782225-9E7D60AE-E347-40CB-81E6-CAE7CB86706AQ28074573-902A7B10-CE64-4F35-ABCD-B0C6AC5BCDD6Q28076978-533EE26B-08A5-4997-9B2E-C9652879EC53Q30238940-D022FF79-352C-410C-B8A1-3889045FD307Q33601593-C4F36165-50B7-4A77-A1C8-F8478394CCCEQ33625568-A2178ACD-F150-4701-AF88-1C3E4D068C12Q33626249-828DE54C-EC46-49F2-97DD-08240FE3872CQ33731855-0A410F44-239F-41B7-A4EE-E67BAEF68565Q33820904-65AE1E1F-E597-45A4-8B86-D222904B248AQ33835709-020935F2-D6BE-44A0-8A72-3EAB01B6AA78Q33871321-A729AB11-EB4D-41F6-8AAB-7365242E1F3DQ33871397-D534CB2A-7F5C-418C-A3FD-095EC5567C4DQ36001903-DD3BEADC-9534-4DFE-BCFE-705B2BCB6EAAQ36301818-3ECBF0E7-81D4-42C5-A032-5DD95D6DB40AQ36345951-2A3C6027-DC93-4884-AEAF-5333D9C6A5A0Q36357997-BFD0E9AD-49D5-4038-8E3B-C04460D1D45BQ36424791-FF894B32-C598-4F67-A807-A97A1FB4963AQ36435496-1F4C5B00-41BC-44F5-8835-FB849BCF599EQ36541052-0110E46D-10A6-40A0-A0A9-FAE575FC3C49Q36960633-48186465-765D-4781-AC12-EB5D29740557Q37018165-932A5E2D-88AA-4CD5-9E5D-79E11F256B93Q37055206-FB8E5D0E-9A45-48E5-B5A6-E90BB7AE05ACQ37114983-A5BB747A-8D90-40B3-8730-16BF15AEED79Q37632127-CB575D7B-F21A-4BA1-8D22-34308528349FQ38599975-7885810C-D74C-43E9-AC6D-A7A1E8E704B9Q38602771-4E6DF3B9-C123-4024-8F8F-76374368871AQ38619164-4F3E5988-4EB9-4D7A-9EFC-622F08078621Q38622754-F68F9FD6-6ACF-443F-BA5D-F5A7736DBDFAQ38642435-583B0AA2-3359-455A-A1CF-66566D4DEB64Q38658251-B07F8531-9398-4983-BD5B-E8C118C93DA7Q38698155-0CA99B51-FCC7-4006-8D6C-604EC220EFCEQ38740284-530898DB-38AF-469A-8F90-D126A4A8D4EDQ38798623-95EBEAC7-990E-4EEC-A403-5783CC87A0ADQ38798654-D6A7CEC1-6EDE-48D4-B983-7A60496B6BB8Q38821464-C67BADBF-8772-49C0-B5AD-3C557B79BA75Q38822815-AF20D06B-33DE-44B4-8D6D-DA93BD97CA06
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
SGLT2 Inhibitors May Predispose to Ketoacidosis
@ast
SGLT2 Inhibitors May Predispose to Ketoacidosis
@en
SGLT2 Inhibitors May Predispose to Ketoacidosis
@nl
type
label
SGLT2 Inhibitors May Predispose to Ketoacidosis
@ast
SGLT2 Inhibitors May Predispose to Ketoacidosis
@en
SGLT2 Inhibitors May Predispose to Ketoacidosis
@nl
prefLabel
SGLT2 Inhibitors May Predispose to Ketoacidosis
@ast
SGLT2 Inhibitors May Predispose to Ketoacidosis
@en
SGLT2 Inhibitors May Predispose to Ketoacidosis
@nl
P2093
P2860
P3181
P356
P1476
SGLT2 Inhibitors May Predispose to Ketoacidosis
@en
P2093
Jenny E. Blau
Kristina I. Rother
Simeon I. Taylor
P2860
P304
P3181
P356
10.1210/JC.2015-1884
P407
P577
2015-08-01T00:00:00Z